Evidence map›Paper›PMID 42010118›Full record

ArticleNature medicine2026

Microbiome signature of Parkinson's disease in healthy and genetically at-risk individuals.

Elisa Menozzi, Yani Ren, Mallia Geiger, Jane Macnaughtan, Micol Avenali, Marco Toffoli, Marine Gilles, Rosaria Calabrese, Pierfrancesco Mitrotti, Luca Gallo and 25 more

Abstract read
In one paragraph

Article in Nature medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Review
  2. The Mind From Within: Visceral Roots of Human Cognition.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026
    Review
  3. Review
  4. Article
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

35 authors.

Elisa MenozziDepartment of Clinical and Movement Neurosciences, UCL Queen Square Institute of Neurology, London, UK.ORCID http://orcid.org/0000-0003-3565-7910
Yani RenAligning Science Across Parkinson's (ASAP) Collaborative Research Network, Chevy Chase, MD, USA.
Mallia GeigerAligning Science Across Parkinson's (ASAP) Collaborative Research Network, Chevy Chase, MD, USA.
Jane MacnaughtanAligning Science Across Parkinson's (ASAP) Collaborative Research Network, Chevy Chase, MD, USA.
Micol AvenaliDepartment of Brain and Behavioral Sciences, University of Pavia, Pavia, Italy.
Marco ToffoliDepartment of Clinical and Movement Neurosciences, UCL Queen Square Institute of Neurology, London, UK.
Marine GillesUniversité Paris-Saclay, INRAE, MetaGenoPolis, Jouy-en-Josas, France.
Rosaria CalabreseIRCCS Mondino Foundation, Pavia, Italy.ORCID http://orcid.org/0009-0008-6632-4653
Pierfrancesco MitrottiDepartment of Brain and Behavioral Sciences, University of Pavia, Pavia, Italy.
Luca GalloDepartment of Brain and Behavioral Sciences, University of Pavia, Pavia, Italy.ORCID http://orcid.org/0009-0007-3693-0380
Alexandre FamechonAligning Science Across Parkinson's (ASAP) Collaborative Research Network, Chevy Chase, MD, USA.ORCID http://orcid.org/0009-0009-6298-3755
Sara Lucas Del PozoDepartment of Clinical and Movement Neurosciences, UCL Queen Square Institute of Neurology, London, UK.
Roxana MezabrovschiDepartment of Clinical and Movement Neurosciences, UCL Queen Square Institute of Neurology, London, UK.ORCID http://orcid.org/0000-0001-8580-0629
Sofia KoletsiDepartment of Clinical and Movement Neurosciences, UCL Queen Square Institute of Neurology, London, UK.
Nadine LoeffladDepartment of Clinical and Movement Neurosciences, UCL Queen Square Institute of Neurology, London, UK.
Selen YalkicDepartment of Clinical and Movement Neurosciences, UCL Queen Square Institute of Neurology, London, UK.ORCID http://orcid.org/0000-0002-9811-6612
Naomi LimbachiyaDepartment of Clinical and Movement Neurosciences, UCL Queen Square Institute of Neurology, London, UK.
Frederick ClasenCentre for Host-Microbiome Interactions, Faculty of Dentistry, Oral & Craniofacial Sciences, King's College London, London, UK.
Suleyman YildirimDepartment of Medical Microbiology, Istanbul Medipol University International School of Medicine, Istanbul, Turkey.
Saeed ShoaieCentre for Host-Microbiome Interactions, Faculty of Dentistry, Oral & Craniofacial Sciences, King's College London, London, UK.ORCID http://orcid.org/0000-0001-5834-4533
Hervé BlottièreAligning Science Across Parkinson's (ASAP) Collaborative Research Network, Chevy Chase, MD, USA.
Christian MorabitoAligning Science Across Parkinson's (ASAP) Collaborative Research Network, Chevy Chase, MD, USA.ORCID http://orcid.org/0000-0002-3193-7299
Aymeric DavidAligning Science Across Parkinson's (ASAP) Collaborative Research Network, Chevy Chase, MD, USA.
Benoit QuinquisAligning Science Across Parkinson's (ASAP) Collaborative Research Network, Chevy Chase, MD, USA.ORCID http://orcid.org/0000-0002-7573-969X
Nicolas PonsAligning Science Across Parkinson's (ASAP) Collaborative Research Network, Chevy Chase, MD, USA.
Emmanuelle Le ChatelierUniversité Paris-Saclay, INRAE, MetaGenoPolis, Jouy-en-Josas, France.ORCID http://orcid.org/0000-0002-2724-0536
Franco ValzaniaNeurology Unit, Azienda Unità Sanitaria Locale-IRCCS di Reggio Emilia, Reggio Emilia, Italy.
Francesco CavallieriNeurology Unit, Azienda Unità Sanitaria Locale-IRCCS di Reggio Emilia, Reggio Emilia, Italy.ORCID http://orcid.org/0000-0001-5836-1982
Valentina FioravantiNeurology Unit, Azienda Unità Sanitaria Locale-IRCCS di Reggio Emilia, Reggio Emilia, Italy.
Giulia ToschiNeurology Unit, Azienda Unità Sanitaria Locale-IRCCS di Reggio Emilia, Reggio Emilia, Italy.
Fabio BlandiniDepartment of Brain and Behavioral Sciences, University of Pavia, Pavia, Italy.
Mathieu AlmeidaAligning Science Across Parkinson's (ASAP) Collaborative Research Network, Chevy Chase, MD, USA.
Stanislav Dusko EhrlichDepartment of Clinical and Movement Neurosciences, UCL Queen Square Institute of Neurology, London, UK. s.ehrlich@ucl.ac.uk.ORCID http://orcid.org/0000-0002-7563-4046
Victoria MeslierAligning Science Across Parkinson's (ASAP) Collaborative Research Network, Chevy Chase, MD, USA. victoria.meslier@gmail.com.ORCID http://orcid.org/0000-0003-2699-0092
Anthony H V SchapiraDepartment of Clinical and Movement Neurosciences, UCL Queen Square Institute of Neurology, London, UK. a.schapira@ucl.ac.uk.ORCID http://orcid.org/0000-0002-3018-3966

Funding

EU Joint Programme - Neurodegenerative Disease Research (Programi i Përbashkët i BE-së për Kërkimet mbi Sëmundjet Neuro-degjeneruese) MR/T046007/1Michael J. Fox Foundation for Parkinson's Research (Michael J. Fox Foundation) ASAP-000420
6 · The paper itself

Abstract

Parkinson's disease (PD) is a major cause of disability. GBA1 variants are the most common genetic risk factor for PD and increase the risk up to 30-fold. Why only approximately 20% of GBA1 variant carriers develop PD remains unknown. Here, by combining clinical and fecal metagenomics data from 271 patients with PD, from 43 carriers of GBA1 variants not manifesting PD symptoms (GBA-NMC) and from 150 healthy controls, and using an innovative microbiome analysis, combining differential abundance of species and coherence of differential abundance variation between the groups as assessed by Cliff's delta (δ), we show that the composition of a large component of the gut microbiome (approximately 25%) in GBA-NMC is intermediate between healthy controls and patients with PD. This component is strongly correlated with disease progression in patients and prodromal symptoms suggestive of future development of PD in both GBA-NMC and healthy individuals. We found microbiome alterations similar to those described here in three independent cohorts from the United States, Korea and Turkey, totaling 638 patients with PD and 319 healthy controls, and we conclude that gut microbiome alterations can identify both genetically and non-genetically at-risk individuals in the general population who may be progressing toward PD, thus serving as an early marker of disease development in the premanifest phase.

Indexed as

Gastrointestinal MicrobiomeGenetic Predisposition to DiseaseGlucosylceramidaseMicrobiotaParkinson DiseaseAgedCase-Control StudiesDisease ProgressionFecesFemaleHumansMaleMetagenomicsMiddle AgedRisk FactorsGBA protein, humanGlucosylceramidase

Identifiers

PMID42010118
PMCPMC13279262

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.